{
  "paper_id": "5e5523ab9299981aa6dc40d0ee209a73cbdb5ab8",
  "metadata": {
    "title": "Insuffisance Respiratoire Aiguë chez le patient immunodéprimé : Quelle approche diagnostique ?",
    "coda_data_split": "test",
    "coda_paper_id": 25,
    "coda_has_expert_labels": false,
    "subset": "custom_license"
  },
  "abstract": [
    {
      "original_text": "1 Brenner H. : Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet 2002 ; 360 : 1131-35. 2 Linker C, Damon L, Ries C, Navarro W : Intensifi ed and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. KC : Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005 ; 352 : 2487-98. AE, Capdeville R, Druker BJ : IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronicphase chronic myeloid leukemia. N Engl J Med 2003 ; 348 : 994-1004.",
      "sentences": [
        [
          {
            "segment_text": "1 Brenner H. : Long-term survival rates of cancer patients achieved by the end of the 20th century : a period analysis .",
            "crowd_label": "background"
          }
        ],
        [
          {
            "segment_text": "Lancet 2002 ; 360 : 1131-35 .",
            "crowd_label": "other"
          }
        ],
        [
          {
            "segment_text": "2 Linker C , Damon L ,",
            "crowd_label": "other"
          },
          {
            "segment_text": "Ries C , Navarro W : Intensifi ed and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia .",
            "crowd_label": "background"
          }
        ],
        [
          {
            "segment_text": "KC : Assessment of Proteasome Inhibition for Extending Remissions ( APEX ) Investigators .",
            "crowd_label": "background"
          }
        ],
        [
          {
            "segment_text": "Bortezomib or high-dose dexamethasone for relapsed multiple myeloma .",
            "crowd_label": "background"
          }
        ],
        [
          {
            "segment_text": "N Engl J Med 2005 ; 352 : 2487-98 .",
            "crowd_label": "other"
          }
        ],
        [
          {
            "segment_text": "AE , Capdeville R , Druker BJ : IRIS Investigators .",
            "crowd_label": "other"
          }
        ],
        [
          {
            "segment_text": "Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronicphase chronic myeloid leukemia .",
            "crowd_label": "finding"
          }
        ],
        [
          {
            "segment_text": "N Engl J Med 2003 ; 348 : 994-1004 .",
            "crowd_label": "other"
          }
        ]
      ]
    }
  ],
  "abstract_stats": {
    "paragraph_num": "1",
    "sentence_num": "9",
    "segment_num": "10",
    "token_num": "124"
  }
}